Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · adults with anxiety disorders
1 finding from 1 review
Adverse events at post‐treatment ‐ not reported · adults with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant satisfaction Indexed by a mix of qualitative and quantitative self‐report measures · adults with anxiety disorders
1 finding from 1 review
Clinically important improvement in anxiety at post‐treatment Indexed by a standardized interview or clinically accepted measure cut‐off score1 · patients with anxiety disorders
1 finding from 1 review
Disorder‐specific anxiety symptom severity at post‐treatment Indexed by a range of disorder‐specific self‐report measures · patients with anxiety disorders
1 finding from 1 review
Anxiety · patients with anxiety disorders
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with cognitive behavioural therapy + placebo (very low certainty).
1 finding from 1 review
Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis
It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: specific ‐ doctors' assessment of adverse effects… compared with cognitive behavioural therapy + placebo (very low certainty).
1 finding from 1 review
QoL · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with cognitive behavioural therapy + placebo (very low certainty).
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ < 12 months · schizophrenia
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes global state ‐ number of participants with relapse/exacerbations of… compared with CBT plus antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · schizophrenia
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with CBT plus antipsychotics (very low certainty).
1 finding from 1 review
Level of functioning · schizophrenia
1 finding from 1 review
Risk for at least one adverse event per patient · schizophrenia
Summary of findings table ‐ CBT without antipsychotics may leads to lower adverse events ‐ Participants with at least one AE (separated time… compared with CBT plus antipsychotics (low certainty).
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review
Leaving the study early · Adults with PTSD for at least 3 months
1 finding from 1 review